BCL2 and colorectal carcinoma: Importantly, as the combined inhibition of BCL-2 and BCL-XL with ABT-199/A-1155463 mirrors the efficacy of the BCL-2/BCL-XL/BCL-W inhibitor ABT-263, these data suggest that the role of BCL-W in protecting CRC cell lines is minimal (Figure S2B).